Last reviewed 2026-06-10 · How we verify

Vasomotor symptoms due to menopause — Treatment Landscape & Competitive Intelligence

Vasomotor symptoms due to menopause (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Vasomotor symptoms due to menopause, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Astellas Pharma · 1 drug in Vasomotor symptoms due to menopause

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Vasomotor symptoms due to menopause:

• Vasomotor symptoms due to menopause treatment updates — RSS
• Vasomotor symptoms due to menopause treatment updates — Atom
• Vasomotor symptoms due to menopause treatment updates — JSON

Cite this brief

Drug Landscape (2026). Vasomotor symptoms due to menopause — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/vasomotor-symptoms-due-to-menopause. Accessed 2026-06-10.

Related

• Vasomotor symptoms due to menopause full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing